publication date: Dec. 17, 2013
The lead author of a paper that argued that the prostate cancer immunotherapy Provenge endangered lives of cancer patients has entered a settlement agreement with the Securities and Exchange Commission.
The agreement states that Marie Huber, an analyst at a hedge fund, had prepared and anonymously circulated a paper about Provenge (sipuleucel-T) at a time when her put options in Dendreon Inc., the drug’s sponsor, were about to expire.
 | NCI Urged to Boost Gastric Cancer Funding A group of members of both chambers of Congress is urging NCI to increase funding for research in gastric cancers—the latest in a string of advocacy initiatives to carve out fiscal support for specific diseases.
|
 | In Brief
Lenora Johnson to leave NCI Office of Communications Adrienne Lang steps down as VP for executive operations at MD Anderson Cancer Center Michael Foley selected to lead the Tri-Institutional Therapeutics Discovery Institute Inc. Beti Thompson to present AACR Distinguished Lecture on Cancer Health Disparities
FDA News Supplemental new drug application for Nexavar tablets (sorafenib) approved 510(k) clearance granted to an estrogen receptor image analysis and digital read application for breast cancer Aptima HPV 16 18/45 genotype assay approved Priority Review granted to ramucirumab as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy FDA and the European Medicines Agency grant orphan drug designation to IMAB362
|
